AstraZeneca, Amgen’s tezepelumab wins ‘breakthrough’ status
AstraZeneca and Amgen’s tezepelumab has won breakthrough therapy status in the US for its potential to treat severe asthma without an eosinophilic phenotype.
Read More
Tag: TSLP
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
